Top 20 Pharmaceutical Companies at risk: Market Share loses in Emerging Markets
•Download as PPTX, PDF•
2 likes•842 views
Increasing relevance of Emerging Markets in Global Pharmaceutical and Top 20 Pharmaceutical Companies limited success in this segment is driving to a Market Shape deep change. It is expected to be even more significant in the next 5 years
Recommended
More Related Content
What's hot
What's hot (17)
Similar to Top 20 Pharmaceutical Companies at risk: Market Share loses in Emerging Markets
Similar to Top 20 Pharmaceutical Companies at risk: Market Share loses in Emerging Markets (20)
Recently uploaded
Recently uploaded (20)
Top 20 Pharmaceutical Companies at risk: Market Share loses in Emerging Markets
- 1. Top 20 Pharmaceutical at risk Redefining the Pharmaceutical Global Market
- 2. From 2008 to 2012, Top 20 Pharma reduced 4% market share in Global Pharma - 200.00 400.00 600.00 800.00 1,000.00 1,200.00 2008 2012 Global Pharma Market Top 20 Pharmaceutical Companies MS= 55% MS= 51% +13% +20% Top 20 Novartis, Pfizer, Merck, Sanofi, Roche, Glaxo, Astra Zeneca Johnson & Johnson Abbvie, Teva, Lilly, Amgen, Boehringer Ingelheim, Bayer, Takeda, BMS, Novo Nordisk, Daichi,Otsuka Mylan
- 3. But, while Top 20 MS’s lost 1% in Developed Markets between 2008 and 2012… - 100.00 200.00 300.00 400.00 500.00 600.00 700.00 800.00 2008 2012 Developed Pharma Market Top 20 Pharmaceutical Companies in D. Markets MS= 60% MS= 59% +7% +9% Top 20 Novartis, Pfizer, Merck, Sanofi, Roche, Glaxo, Astra Zeneca Johnson & Johnson Abbvie, Teva, Lilly, Amgen, Boehringer Ingelheim, Bayer, Takeda, BMS, Novo Nordisk, Daichi,Otsuka Mylan
- 4. …Top 20 lost as much as 4% MS in Emerging Markets between 2008 and 2012 - 50.00 100.00 150.00 200.00 250.00 300.00 350.00 2008 2012 Emerging Markets Top 20 Pharmaceutical Companies in E.Markets MS= 37% MS= 33% +41% +57% Top 20 Novartis, Pfizer, Merck, Sanofi, Roche, Glaxo, Astra Zeneca Johnson & Johnson Abbvie, Teva, Lilly, Amgen, Boehringer Ingelheim, Bayer, Takeda, BMS, Novo Nordisk, Daichi,Otsuka Mylan
- 5. Emerging Markets represent 30% of the Global Pharma in 2013 and will raise to 40% by 2017 According to Emergpharma`s Pannel Forecast - 100.00 200.00 300.00 400.00 500.00 600.00 2012 2013 2014 2015 2016 2017 x1000 USD Estimated CAGR (%) 10,8%
- 6. If Top 12 Pharma keep same trend than the last 3 years, in 2017 global MS in Emerging Markets will be down 5% - 20.00 40.00 60.00 80.00 100.00 120.00 140.00 160.00 180.00 2012 2013 2014 2015 2016 2017 Top 20 Following the Market Top 20 Present Trend -26,8 bn MS (Emerging Markets): 33% MS (Emerging Markets): 28%
- 7. In Summary • From 2008 to 2012 Global Pharmaceutical Market is moving towards Emerging Markets and in 2017 around 40% of Pharmaceutical Revenues will be produced in (today) non Developed Countries • In this market segment, Top 20 (51% of the Global Market) have a significant less MS than in Developed Markets (33% vs 60%) • Last 5 years Top 20 are losing MS globally, although 4 times faster in Emerging Markets • If trend keeps similar, in 2017 Top 20 will have lost an additional 5% MS in Emerging Markets and, even keeping MS in the Developed Segment, their presence in Global Market will be reduced to 46%, almost 1% per year.
- 8. In Summary (II) • Although Top 20 Pharmaceuticals consider Emerging Markets one of the core growth drivers, representing a significant and increasing percentage of their global growth, they are steadily losing market share • At the same time, non Top 20 in Emerging Markets are clearly growing faster than the market although, due to a lack of reliable and usable information on segment dynamics, the fact is not being capitalized on accordingly by the financial community • It is mandatory to fill the gap in order to shape the new Global Pharmaceutical Market on a more effective way and get important lessons to be applied by established MNCs, in particular in their M&A strategy
- 9. Get More information Send an email to: Joseignacio.diaz@yahoo.com Or visit our Website www.emergpharma.com